Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | USP8 | P40818 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21798555 | 0.85 | CA1 (0.44) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL4805734 | 0.79 | CA1 (0.42) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL7304055 | 0.78 | IMPDH2 (0.41) | CA1CA2CYP2A6 | |
| SCHEMBL6668843 | 0.75 | CA1 (0.39) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL6672925 | 0.75 | CA1 (0.39) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL5749158 | 0.74 | CA1 (0.41) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL5748490 | 0.74 | CA1 (0.44) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL9710751 | 0.73 | CA1 (0.40) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL29489128 | 0.71 | CA1 (0.64) | CA1CA2ALDH1A1KDM4EGAA | |
| SCHEMBL149126 | 0.71 | CA1 (0.64) | CA1CA2ALDH1A1KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7550455-B2 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-23 | — | — | US | claimed |
| EP-1689748-B1 | NOVEL 8-(PIPERAZINE-1-YL)- AND 8-( 1,4 DIAZEPAN-1-YL)-XANTHINE, THE PRODUCTION AND USE THEREOF IN THE FROM OF A DRUG | BOEHRINGER INGELHEIM INT (DE) | 2008-02-13 | — | — | EP | claimed |
| JP-2007513989-A | — | — | 2007-05-31 | — | — | JP | claimed |
| JP-2007512280-A | — | — | 2007-05-17 | — | — | JP | claimed |
| US-7217711-B2 | Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-15 | — | — | US | claimed |
| EP-1742949-A1 | NOVEL-2-(PIPERAZIN-1-YL)-AND-2-([1,4]DIAZEPAN-1-YL)-IMIDAZO[4,5-D]PYRIDAZIN-4-ONE, PRODUCTION AND USE THEREOF AS MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS | Boehringer Ingelheim International GmbH (DE) | 2007-01-17 | — | — | EP | claimed |
| EP-1689748-A1 | NOVEL 8-(PIPERAZINE-1-YL)- AND 8-( 1,4|DIAZEPAN-1-YL)-XANTHINE, THE PRODUCTION AND USE THEREOF IN THE FROM OF A DRUG | Boehringer Ingelheim International GmbH (DE) | 2006-08-16 | — | — | EP | claimed |
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | US | claimed |
| WO-2005058901-A1 | NOVEL 2-(PIPERAZIN-1-YL)- AND 2-([1,4]DIAZEPAN-1-YL)- IMIDAZO[4,5-D]PYRIDAZIN-4-ONE, PRODUCTION AND USE THEREOF AS MEDICAMENT FOR THE TREATMENT OF DIABETES MELLITUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-30 | — | — | WO | claimed |
| US-20050130985-A1 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| WO-2005051950-A1 | NOVEL 8-(PIPERAZINE-1-YL)- AND 8-([1,4]DIAZEPAN-1-YL)-XANTHINE, THE PRODUCTION AND USE THEREOF IN THE FROM OF A DRUG | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-06-09 | — | — | WO | claimed |
| WO-2024038818-A1 | FUSED-RING POLYAZAACENE COMPOUND, AND PHOTOELECTRIC CONVERSION ELEMENT OR ORGANIC ELECTRONIC ELEMENT CONTAINING SAME | 東ソー株式会社 | 2024-02-22 | — | — | WO | disclosed |
| CN-112955422-B | polycyclic compound | 三菱瓦斯化学株式会社 | 2023-08-22 | — | — | CN | disclosed |
| US-20220059783-A1 | COMPOSITION, PHOTOELECTRIC CONVERSION ELEMENT, AND IMAGING DEVICE | PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD. (JP) | 2022-02-24 | — | — | US | disclosed |
| CN-110759919-B | Pyrene quinone organic compound and application thereof | 广州华睿光电材料有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-0583971-A1 | Piperidine derivatives | SANKYO COMPANY LIMITED (JP) | 1994-02-23 | — | — | EP | disclosed |
| CN-1064683-A | New beta-amino-alpha-hydroxycarboxylic acids and uses thereof | SANKYO CO (JP) | 1992-09-23 | — | — | CN | disclosed |
| EP-0498680-A1 | New beta-amino-alpha-hydroxycarboxylic acids and their use | Sankyo Company Limited (JP) | 1992-08-12 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| CN-1052481-A | Lipoid category-A with immunocompetence and anti-tumor activity is like thing | SANKYO CO (JP) | 1991-06-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171093-A1 | New piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutial compositions | DPP4, DPP3, DPP7 | CA1 2493/4885CA2 924/4885ALDH1A1 285/4885 |
| US-20050130985-A1 | 8-(piperazin-1yl)- and 8-([1,4]diazepan-1yl)-xanthines, the preparation thereof and their use as pharmaceutical composition | DPP8, DPP4, DPP7 | CA1 970/4885CA2 872/4885ALDH1A1 247/4885 |
| US-20220059783-A1 | COMPOSITION, PHOTOELECTRIC CONVERSION ELEMENT, AND IMAGING DEVICE | INTS9, TRRAP, NR2E3 | CA1 3372/4885CA2 3199/4885ALDH1A1 3452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.